Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients.

摘要: Cytochrome P450 1B1 (CYP1B1) is widely expressed in human malignancies, but silent most normal tissues. Importantly, the protein believed to play an important role survival and growth of cancer cells a stressed environment, e.g., as result hypoxia or chemotherapy. Thus, targeting CYP1B1 represents potentially successful strategy treatment metastatic cancer, by therapeutic vaccination. Herein, we describe characterization novel peptide from (CYP240), which spontaneously recognized CD8 T patients. Interestingly, binds both leukocyte antigen (HLA)-A1 HLA-B35. Hence, peripheral blood lymphocytes total 49 patients (25 melanoma, 13 RCC, 11 breast cancer; 41 HLA-A1 positive, 8 HLA-B35 positive) were analyzed for reactivity taking advantage EliSpot assay. Rare strong responses detected HLA-A1-positive patients, more frequent HLA-B35-positive No against could be healthy donors. Furthermore, demonstrated that peptide-specific able lyze target presenting on surface. The characterized CYP240 presented herein opens avenue broader recruitment vaccination trials CYB1B1.